Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT Journal Article
| Authors: | Ceberio, I.; Dai, K.; Devlin, S. M.; Barker, J. N.; Castro-Malaspina, H.; Goldberg, J. D.; Giralt, S.; Adel, N. G.; Perales, M. A. |
| Article Title: | Safety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT |
| Abstract: | Antifungal prophylaxis with azoles is considered standard in allogeneic hematopoietic SCT (allo-HSCT). Although sirolimus is being used increasingly for the prevention of GVHD, it is a substrate of CYP3A4, which is inhibited by voriconazole, and concurrent administration can lead to significantly increased exposure to sirolimus. We identified 67 patients with hematologic malignancies who underwent allo-HSCT with sirolimus, tacrolimus and low-dose MTX and received concomitant voriconazole prophylaxis from April 2008 to June 2011. All patients underwent a non-myeloablative or reduced-intensity conditioned allo-HSCT. Patients received sirolimus and voriconazole concurrently for a median of 113 days. The median daily dose reduction of sirolimus at the start of coadministration was 90%. The median serum sirolimus trough levels before and at steady state of coadministration were 5.8 ng/mL (range: 0-47.6) and 6.1 ng/mL (range: 1-14.2) (P = 0.45), respectively. One patient with an average sirolimus level of 6 ng/mL developed sirolimus-related thrombotic microangiopathy that resolved after sirolimus discontinuation. No sinusoidal obstructive syndrome was reported. Seventeen patients (25%) prematurely discontinued voriconazole because of the adverse events. Only two patients (3%) presented with possible invasive fungal infections at day 100. We demonstrate that sirolimus and voriconazole coadministration with an empiric 90% sirolimus dose reduction and close monitoring of sirolimus trough levels is safe and well tolerated. © 2015 Macmillan Publishers Limited. |
| Keywords: | adult; aged; major clinical study; drug tolerability; dose response; drug dose reduction; drug safety; drug withdrawal; unspecified side effect; methotrexate; low drug dose; liver toxicity; nephrotoxicity; steady state; qt prolongation; creatinine; creatinine blood level; patient identification; rash; hematologic malignancy; graft versus host reaction; reduced intensity conditioning; allogeneic hematopoietic stem cell transplantation; drug monitoring; drug blood level; graft rejection; drug substitution; tacrolimus; visual disorder; thrombotic thrombocytopenic purpura; rapamycin; mycosis; voriconazole; liver venoocclusive disease; human; male; female; priority journal; article |
| Journal Title: | Bone Marrow Transplantation |
| Volume: | 50 |
| Issue: | 3 |
| ISSN: | 0268-3369 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2015-03-01 |
| Start Page: | 438 |
| End Page: | 443 |
| Language: | English |
| DOI: | 10.1038/bmt.2014.286 |
| PROVIDER: | scopus |
| PMCID: | PMC4379043 |
| PUBMED: | 25599164 |
| DOI/URL: | |
| Notes: | Export Date: 2 September 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work